Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in its eClinical Suite

Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in its eClinical Suite

Boston, MA, December 10, 2009 -
Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today introduced unique product convergence between its DataLabs® EDC solution and ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. New functionality in the DataLabs EDC solution has created advanced interoperability with the ClinPhone RTSM technologies, allowing the use of either system for randomizing patients and dispensing medication.

"In order to further simplify workflow and enable users to perform activities using whichever system is best suited to their preferences, we are continuing to blur the boundaries between our EDC and RTSM solutions," said Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics. "Fueled by the next version of Perceptive's EDC solution, this latest achievement in true convergence represents a radical shift in the way technologies can be used together to accelerate clinical trials."

The convergence between the EDC and RTSM solutions in Perceptive's eClinical Suite significantly simplifies workflow, making it easy for clinical site personnel to use both technology solutions seamlessly within a single clinical trial. The DataLabs EDC system can be used as an interface to the ClinPhone RTSM technologies so that clinical sites can randomize and dispense medication in real time. Users can perform these activities without logging into a second system, eliminating the need to enter data via phone or online, then reconcile within the EDC system at a later time. This approach increases efficiency and productivity for sponsors and sites, and ultimately reduces the costs associated with clinical research.

Key features of the greater convergence available in Perceptive's EDC-RTSM solutions include:

â– Patient Randomization - Enables sites to randomize a patient from the DataLabs EDC system, an advanced capability not available in typical stand alone EDC systems
â– Medication dispensing - Sites can request dispensation of medication or devices for patients as needed, directly from the EDC system, without logging into a second system
â– Request Replacement - Sites can request a replacement for a previously assigned medication or device in the case of damage, loss, or other reason
The DataLabs system, a leading EDC solution from Perceptive Informatics with a user-friendly interface, is suitable for all types and sizes of clinical trials. In addition to the tight interoperability with RTSM functionality, DataLabs provides a single electronic clinical data management platform to unify the functionality of paper data entry (PDE) with the flexibility of EDC. The hybrid capability enables studies to include sites using paper CRFs and support existing paper processes such as collection of extraneous paper data, providing sponsors with the ability to choose their preferred method of data collection.

For more information about the eClinical Suite from Perceptive Informatics, visit


About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.